APO Research
Talk to an analyst

APO RESEARCH · REPORT

Restless Legs Syndrome

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Restless Legs Syndrome Market Analysis and Forecast 2026-2032

29 December 2025190 pages

Choose your research edition.

Industry ResearchRestless Legs Syndrome Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Restless Legs Syndrome Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Restless Legs Syndrome Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Restless Legs Syndrome Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Restless Legs Syndrome Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Restless Legs Syndrome market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Restless Legs Syndrome is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Restless Legs Syndrome is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Restless Legs Syndrome is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Restless Legs Syndrome is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Restless Legs Syndrome include UCB SA, Omeros Corporation, Manhattan Pharmaceuticals, Ligand Pharmaceuticals Incorporated, Kyowa Hakko Kirin Co., Jazz Pharmaceuticals, Inc., GlaxoSmithKline plc., Boehringer Ingelheim GmbH and axxonis Pharma AG, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Restless Legs Syndrome, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Restless Legs Syndrome, also provides the revenue of main regions and countries. Of the upcoming market potential for Restless Legs Syndrome, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Restless Legs Syndrome revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Restless Legs Syndrome market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Restless Legs Syndrome revenue, projected growth trends, production technology, application and end-user industry.

Restless Legs Syndrome Segment by Company

UCB SA

Omeros Corporation

Manhattan Pharmaceuticals

Ligand Pharmaceuticals Incorporated

Kyowa Hakko Kirin Co.

Jazz Pharmaceuticals, Inc.

GlaxoSmithKline plc.

Boehringer Ingelheim GmbH

axxonis Pharma AG

Astellas

Arbor Pharmaceuticals

Restless Legs Syndrome Segment by Type

Pharmacological Therapy

Non-Pharmacological Therapy

Restless Legs Syndrome Segment by Application

Above 50 Years Old

Below 35 Years Old

From 35 to 50 Years Old

Restless Legs Syndrome Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Restless Legs Syndrome market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Restless Legs Syndrome and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Restless Legs Syndrome.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Restless Legs Syndrome in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Restless Legs Syndrome company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Restless Legs Syndrome revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Restless Legs Syndrome Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Pharmacological Therapy Major Player Table 3. Non-Pharmacological Therapy Major Player Table 4. Global Restless Legs Syndrome Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Above 50 Years Old Major Player Table 6. Below 35 Years Old Major Player Table 7. From 35 to 50 Years Old Major Player Table 8. Restless Legs Syndrome Industry Trends Table 9. Restless Legs Syndrome Industry Drivers Table 10. Restless Legs Syndrome Industry Opportunities and Challenges Table 11. Restless Legs Syndrome Industry Restraints Table 12. Global Restless Legs Syndrome Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Restless Legs Syndrome Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Restless Legs Syndrome Market Share by Region (2021-2026) Table 15. Global Restless Legs Syndrome Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Restless Legs Syndrome Market Share by Region (2027-2032) Table 17. Global Restless Legs Syndrome Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Restless Legs Syndrome Revenue Market Share by Players (2021-2026) Table 19. Global Restless Legs Syndrome Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Restless Legs Syndrome Key Players Headquarters & Area Served Table 21. Global Restless Legs Syndrome Players, Product Type & Application Table 22. Global Restless Legs Syndrome Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Restless Legs Syndrome by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Restless Legs Syndrome Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Restless Legs Syndrome Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Restless Legs Syndrome Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Restless Legs Syndrome Revenue Market Share by Type (2021-2026) Table 29. Global Restless Legs Syndrome Revenue Market Share by Type (2027-2032) Table 30. Global Restless Legs Syndrome Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Restless Legs Syndrome Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Restless Legs Syndrome Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Restless Legs Syndrome Revenue Market Share by Application (2021-2026) Table 34. Global Restless Legs Syndrome Revenue Market Share by Application (2027-2032) Table 35. UCB SA Company Information Table 36. UCB SA Business Overview Table 37. UCB SA Restless Legs Syndrome Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. UCB SA Restless Legs Syndrome Product Portfolio Table 39. UCB SA Recent Development Table 40. Omeros Corporation Company Information Table 41. Omeros Corporation Business Overview Table 42. Omeros Corporation Restless Legs Syndrome Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Omeros Corporation Restless Legs Syndrome Product Portfolio Table 44. Omeros Corporation Recent Development Table 45. Manhattan Pharmaceuticals Company Information Table 46. Manhattan Pharmaceuticals Business Overview Table 47. Manhattan Pharmaceuticals Restless Legs Syndrome Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Manhattan Pharmaceuticals Restless Legs Syndrome Product Portfolio Table 49. Manhattan Pharmaceuticals Recent Development Table 50. Ligand Pharmaceuticals Incorporated Company Information Table 51. Ligand Pharmaceuticals Incorporated Business Overview Table 52. Ligand Pharmaceuticals Incorporated Restless Legs Syndrome Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Ligand Pharmaceuticals Incorporated Restless Legs Syndrome Product Portfolio Table 54. Ligand Pharmaceuticals Incorporated Recent Development Table 55. Kyowa Hakko Kirin Co. Company Information Table 56. Kyowa Hakko Kirin Co. Business Overview Table 57. Kyowa Hakko Kirin Co. Restless Legs Syndrome Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Kyowa Hakko Kirin Co. Restless Legs Syndrome Product Portfolio Table 59. Kyowa Hakko Kirin Co. Recent Development Table 60. Jazz Pharmaceuticals, Inc. Company Information Table 61. Jazz Pharmaceuticals, Inc. Business Overview Table 62. Jazz Pharmaceuticals, Inc. Restless Legs Syndrome Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Jazz Pharmaceuticals, Inc. Restless Legs Syndrome Product Portfolio Table 64. Jazz Pharmaceuticals, Inc. Recent Development Table 65. GlaxoSmithKline plc. Company Information Table 66. GlaxoSmithKline plc. Business Overview Table 67. GlaxoSmithKline plc. Restless Legs Syndrome Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. GlaxoSmithKline plc. Restless Legs Syndrome Product Portfolio Table 69. GlaxoSmithKline plc. Recent Development Table 70. Boehringer Ingelheim GmbH Company Information Table 71. Boehringer Ingelheim GmbH Business Overview Table 72. Boehringer Ingelheim GmbH Restless Legs Syndrome Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Boehringer Ingelheim GmbH Restless Legs Syndrome Product Portfolio Table 74. Boehringer Ingelheim GmbH Recent Development Table 75. axxonis Pharma AG Company Information Table 76. axxonis Pharma AG Business Overview Table 77. axxonis Pharma AG Restless Legs Syndrome Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. axxonis Pharma AG Restless Legs Syndrome Product Portfolio Table 79. axxonis Pharma AG Recent Development Table 80. Astellas Company Information Table 81. Astellas Business Overview Table 82. Astellas Restless Legs Syndrome Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Astellas Restless Legs Syndrome Product Portfolio Table 84. Astellas Recent Development Table 85. Arbor Pharmaceuticals Company Information Table 86. Arbor Pharmaceuticals Business Overview Table 87. Arbor Pharmaceuticals Restless Legs Syndrome Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Arbor Pharmaceuticals Restless Legs Syndrome Product Portfolio Table 89. Arbor Pharmaceuticals Recent Development Table 90. North America Restless Legs Syndrome Revenue by Type (2021-2026) & (US$ Million) Table 91. North America Restless Legs Syndrome Revenue by Type (2027-2032) & (US$ Million) Table 92. North America Restless Legs Syndrome Revenue by Application (2021-2026) & (US$ Million) Table 93. North America Restless Legs Syndrome Revenue by Application (2027-2032) & (US$ Million) Table 94. North America Restless Legs Syndrome Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 95. North America Restless Legs Syndrome Revenue by Country (2021-2026) & (US$ Million) Table 96. North America Restless Legs Syndrome Revenue by Country (US$ Million) & (2027-2032) Table 97. Europe Restless Legs Syndrome Revenue by Type (2021-2026) & (US$ Million) Table 98. Europe Restless Legs Syndrome Revenue by Type (2027-2032) & (US$ Million) Table 99. Europe Restless Legs Syndrome Revenue by Application (2021-2026) & (US$ Million) Table 100. Europe Restless Legs Syndrome Revenue by Application (2027-2032) & (US$ Million) Table 101. Europe Restless Legs Syndrome Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 102. Europe Restless Legs Syndrome Revenue by Country (2021-2026) & (US$ Million) Table 103. Europe Restless Legs Syndrome Revenue by Country (US$ Million) & (2027-2032) Table 104. China Restless Legs Syndrome Revenue by Type (2021-2026) & (US$ Million) Table 105. China Restless Legs Syndrome Revenue by Type (2027-2032) & (US$ Million) Table 106. China Restless Legs Syndrome Revenue by Application (2021-2026) & (US$ Million) Table 107. China Restless Legs Syndrome Revenue by Application (2027-2032) & (US$ Million) Table 108. Asia Restless Legs Syndrome Revenue by Type (2021-2026) & (US$ Million) Table 109. Asia Restless Legs Syndrome Revenue by Type (2027-2032) & (US$ Million) Table 110. Asia Restless Legs Syndrome Revenue by Application (2021-2026) & (US$ Million) Table 111. Asia Restless Legs Syndrome Revenue by Application (2027-2032) & (US$ Million) Table 112. Asia Restless Legs Syndrome Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 113. Asia Restless Legs Syndrome Revenue by Region (US$ Million) & (2021-2026) Table 114. Asia Restless Legs Syndrome Revenue by Region (US$ Million) & (2027-2032) Table 115. SAMEA Restless Legs Syndrome Revenue by Type (2021-2026) & (US$ Million) Table 116. SAMEA Restless Legs Syndrome Revenue by Type (2027-2032) & (US$ Million) Table 117. SAMEA Restless Legs Syndrome Revenue by Application (2021-2026) & (US$ Million) Table 118. SAMEA Restless Legs Syndrome Revenue by Application (2027-2032) & (US$ Million) Table 119. SAMEA Restless Legs Syndrome Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 120. SAMEA Restless Legs Syndrome Revenue by Country (2021-2026) & (US$ Million) Table 121. SAMEA Restless Legs Syndrome Revenue by Country (US$ Million) & (2027-2032) Table 122. Research Programs/Design for This Report Table 123. Authors List of This Report Table 124. Secondary Sources Table 125. Primary Sources List of Figures Figure 1. Restless Legs Syndrome Image Figure 2. Global Restless Legs Syndrome Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Restless Legs Syndrome Market Size Share 2021 VS 2025 VS 2032 Figure 4. Pharmacological Therapy Image Figure 5. Non-Pharmacological Therapy Image Figure 6. Global Restless Legs Syndrome Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Restless Legs Syndrome Market Size Share 2021 VS 2025 VS 2032 Figure 8. Above 50 Years Old Image Figure 9. Below 35 Years Old Image Figure 10. From 35 to 50 Years Old Image Figure 11. Global Restless Legs Syndrome Market Size (US$ Million) & (2021-2032) Figure 12. Global Restless Legs Syndrome Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Restless Legs Syndrome Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Restless Legs Syndrome Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Restless Legs Syndrome Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Restless Legs Syndrome Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Restless Legs Syndrome Revenue Market Share by Type (2021-2032) Figure 19. Global Restless Legs Syndrome Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Restless Legs Syndrome Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Restless Legs Syndrome Revenue Market Share by Application (2021-2032) Figure 22. North America Restless Legs Syndrome Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Restless Legs Syndrome Revenue Share by Type (2021-2032) Figure 24. North America Restless Legs Syndrome Revenue Share by Application (2021-2032) Figure 25. North America Restless Legs Syndrome Revenue Share by Country (2021-2032) Figure 26. United States Restless Legs Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Restless Legs Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Restless Legs Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Restless Legs Syndrome Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Restless Legs Syndrome Revenue Share by Type (2021-2032) Figure 31. Europe Restless Legs Syndrome Revenue Share by Application (2021-2032) Figure 32. Europe Restless Legs Syndrome Revenue Share by Country (2021-2032) Figure 33. Germany Restless Legs Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Restless Legs Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Restless Legs Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Restless Legs Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Restless Legs Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Restless Legs Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Restless Legs Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Restless Legs Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Restless Legs Syndrome Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Restless Legs Syndrome Revenue Share by Type (2021-2032) Figure 43. China Restless Legs Syndrome Revenue Share by Application (2021-2032) Figure 44. Asia Restless Legs Syndrome Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Restless Legs Syndrome Revenue Share by Type (2021-2032) Figure 46. Asia Restless Legs Syndrome Revenue Share by Application (2021-2032) Figure 47. Asia Restless Legs Syndrome Revenue Share by Region (2021-2032) Figure 48. Japan Restless Legs Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Restless Legs Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Restless Legs Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Restless Legs Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Restless Legs Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Restless Legs Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Restless Legs Syndrome Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Restless Legs Syndrome Revenue Share by Type (2021-2032) Figure 56. SAMEA Restless Legs Syndrome Revenue Share by Application (2021-2032) Figure 57. SAMEA Restless Legs Syndrome Revenue Share by Country (2021-2032) Figure 58. Brazil Restless Legs Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Restless Legs Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Restless Legs Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Restless Legs Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Restless Legs Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Restless Legs Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Restless Legs Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Restless Legs Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Restless Legs Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Restless Legs Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Restless Legs Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Pharmacological Therapy
  • Non-Pharmacological Therapy
Applications
  • Above 50 Years Old
  • Below 35 Years Old
  • From 35 to 50 Years Old
Companies covered
  • UCB SA
  • Omeros Corporation
  • Manhattan Pharmaceuticals
  • Ligand Pharmaceuticals Incorporated
  • Kyowa Hakko Kirin Co.
  • Jazz Pharmaceuticals, Inc.
  • GlaxoSmithKline plc.
  • Boehringer Ingelheim GmbH
  • axxonis Pharma AG
  • Astellas
  • Arbor Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Restless Legs Syndrome Market by Type
  3. 1.2.1 Global Restless Legs Syndrome Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Pharmacological Therapy
  5. 1.2.3 Non-Pharmacological Therapy
  6. 1.3 Restless Legs Syndrome Market by Application
  7. 1.3.1 Global Restless Legs Syndrome Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Above 50 Years Old
  9. 1.3.3 Below 35 Years Old
  10. 1.3.4 From 35 to 50 Years Old
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Restless Legs Syndrome Market Dynamics
  1. 2.1 Restless Legs Syndrome Industry Trends
  2. 2.2 Restless Legs Syndrome Industry Drivers
  3. 2.3 Restless Legs Syndrome Industry Opportunities and Challenges
  4. 2.4 Restless Legs Syndrome Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Restless Legs Syndrome Market Perspective (2021-2032)
  2. 3.2 Global Restless Legs Syndrome Growth Trends by Region
  3. 3.2.1 Global Restless Legs Syndrome Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Restless Legs Syndrome Market Size by Region (2021-2026)
  5. 3.2.3 Global Restless Legs Syndrome Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Restless Legs Syndrome Revenue by Players
  2. 4.1.1 Global Restless Legs Syndrome Revenue by Players (2021-2026)
  3. 4.1.2 Global Restless Legs Syndrome Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Restless Legs Syndrome Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Restless Legs Syndrome Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Restless Legs Syndrome Key Players Headquarters & Area Served
  7. 4.4 Global Restless Legs Syndrome Players, Product Type & Application
  8. 4.5 Global Restless Legs Syndrome Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Restless Legs Syndrome Market CR5 and HHI
  11. 4.6.3 2025 Restless Legs Syndrome Tier 1, Tier 2, and Tier 3
5 Restless Legs Syndrome Market Size by Type
  1. 5.1 Global Restless Legs Syndrome Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Restless Legs Syndrome Revenue by Type (2021-2032)
  3. 5.3 Global Restless Legs Syndrome Revenue Market Share by Type (2021-2032)
6 Restless Legs Syndrome Market Size by Application
  1. 6.1 Global Restless Legs Syndrome Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Restless Legs Syndrome Revenue by Application (2021-2032)
  3. 6.3 Global Restless Legs Syndrome Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 UCB SA
  2. 7.1.1 UCB SA Company Information
  3. 7.1.2 UCB SA Business Overview
  4. 7.1.3 UCB SA Restless Legs Syndrome Revenue and Gross Margin (2021-2026)
  5. 7.1.4 UCB SA Restless Legs Syndrome Product Portfolio
  6. 7.1.5 UCB SA Recent Developments
  7. 7.2 Omeros Corporation
  8. 7.2.1 Omeros Corporation Company Information
  9. 7.2.2 Omeros Corporation Business Overview
  10. 7.2.3 Omeros Corporation Restless Legs Syndrome Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Omeros Corporation Restless Legs Syndrome Product Portfolio
  12. 7.2.5 Omeros Corporation Recent Developments
  13. 7.3 Manhattan Pharmaceuticals
  14. 7.3.1 Manhattan Pharmaceuticals Company Information
  15. 7.3.2 Manhattan Pharmaceuticals Business Overview
  16. 7.3.3 Manhattan Pharmaceuticals Restless Legs Syndrome Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Manhattan Pharmaceuticals Restless Legs Syndrome Product Portfolio
  18. 7.3.5 Manhattan Pharmaceuticals Recent Developments
  19. 7.4 Ligand Pharmaceuticals Incorporated
  20. 7.4.1 Ligand Pharmaceuticals Incorporated Company Information
  21. 7.4.2 Ligand Pharmaceuticals Incorporated Business Overview
  22. 7.4.3 Ligand Pharmaceuticals Incorporated Restless Legs Syndrome Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Ligand Pharmaceuticals Incorporated Restless Legs Syndrome Product Portfolio
  24. 7.4.5 Ligand Pharmaceuticals Incorporated Recent Developments
  25. 7.5 Kyowa Hakko Kirin Co.
  26. 7.5.1 Kyowa Hakko Kirin Co. Company Information
  27. 7.5.2 Kyowa Hakko Kirin Co. Business Overview
  28. 7.5.3 Kyowa Hakko Kirin Co. Restless Legs Syndrome Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Kyowa Hakko Kirin Co. Restless Legs Syndrome Product Portfolio
  30. 7.5.5 Kyowa Hakko Kirin Co. Recent Developments
  31. 7.6 Jazz Pharmaceuticals, Inc.
  32. 7.6.1 Jazz Pharmaceuticals, Inc. Company Information
  33. 7.6.2 Jazz Pharmaceuticals, Inc. Business Overview
  34. 7.6.3 Jazz Pharmaceuticals, Inc. Restless Legs Syndrome Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Jazz Pharmaceuticals, Inc. Restless Legs Syndrome Product Portfolio
  36. 7.6.5 Jazz Pharmaceuticals, Inc. Recent Developments
  37. 7.7 GlaxoSmithKline plc.
  38. 7.7.1 GlaxoSmithKline plc. Company Information
  39. 7.7.2 GlaxoSmithKline plc. Business Overview
  40. 7.7.3 GlaxoSmithKline plc. Restless Legs Syndrome Revenue and Gross Margin (2021-2026)
  41. 7.7.4 GlaxoSmithKline plc. Restless Legs Syndrome Product Portfolio
  42. 7.7.5 GlaxoSmithKline plc. Recent Developments
  43. 7.8 Boehringer Ingelheim GmbH
  44. 7.8.1 Boehringer Ingelheim GmbH Company Information
  45. 7.8.2 Boehringer Ingelheim GmbH Business Overview
  46. 7.8.3 Boehringer Ingelheim GmbH Restless Legs Syndrome Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Boehringer Ingelheim GmbH Restless Legs Syndrome Product Portfolio
  48. 7.8.5 Boehringer Ingelheim GmbH Recent Developments
  49. 7.9 axxonis Pharma AG
  50. 7.9.1 axxonis Pharma AG Company Information
  51. 7.9.2 axxonis Pharma AG Business Overview
  52. 7.9.3 axxonis Pharma AG Restless Legs Syndrome Revenue and Gross Margin (2021-2026)
  53. 7.9.4 axxonis Pharma AG Restless Legs Syndrome Product Portfolio
  54. 7.9.5 axxonis Pharma AG Recent Developments
  55. 7.10 Astellas
  56. 7.10.1 Astellas Company Information
  57. 7.10.2 Astellas Business Overview
  58. 7.10.3 Astellas Restless Legs Syndrome Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Astellas Restless Legs Syndrome Product Portfolio
  60. 7.10.5 Astellas Recent Developments
  61. 7.11 Arbor Pharmaceuticals
  62. 7.11.1 Arbor Pharmaceuticals Company Information
  63. 7.11.2 Arbor Pharmaceuticals Business Overview
  64. 7.11.3 Arbor Pharmaceuticals Restless Legs Syndrome Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Arbor Pharmaceuticals Restless Legs Syndrome Product Portfolio
  66. 7.11.5 Arbor Pharmaceuticals Recent Developments
8 North America
  1. 8.1 North America Restless Legs Syndrome Revenue (2021-2032)
  2. 8.2 North America Restless Legs Syndrome Revenue by Type (2021-2032)
  3. 8.2.1 North America Restless Legs Syndrome Revenue by Type (2021-2026)
  4. 8.2.2 North America Restless Legs Syndrome Revenue by Type (2027-2032)
  5. 8.3 North America Restless Legs Syndrome Revenue Share by Type (2021-2032)
  6. 8.4 North America Restless Legs Syndrome Revenue by Application (2021-2032)
  7. 8.4.1 North America Restless Legs Syndrome Revenue by Application (2021-2026)
  8. 8.4.2 North America Restless Legs Syndrome Revenue by Application (2027-2032)
  9. 8.5 North America Restless Legs Syndrome Revenue Share by Application (2021-2032)
  10. 8.6 North America Restless Legs Syndrome Revenue by Country
  11. 8.6.1 North America Restless Legs Syndrome Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Restless Legs Syndrome Revenue by Country (2021-2026)
  13. 8.6.3 North America Restless Legs Syndrome Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Restless Legs Syndrome Revenue (2021-2032)
  2. 9.2 Europe Restless Legs Syndrome Revenue by Type (2021-2032)
  3. 9.2.1 Europe Restless Legs Syndrome Revenue by Type (2021-2026)
  4. 9.2.2 Europe Restless Legs Syndrome Revenue by Type (2027-2032)
  5. 9.3 Europe Restless Legs Syndrome Revenue Share by Type (2021-2032)
  6. 9.4 Europe Restless Legs Syndrome Revenue by Application (2021-2032)
  7. 9.4.1 Europe Restless Legs Syndrome Revenue by Application (2021-2026)
  8. 9.4.2 Europe Restless Legs Syndrome Revenue by Application (2027-2032)
  9. 9.5 Europe Restless Legs Syndrome Revenue Share by Application (2021-2032)
  10. 9.6 Europe Restless Legs Syndrome Revenue by Country
  11. 9.6.1 Europe Restless Legs Syndrome Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Restless Legs Syndrome Revenue by Country (2021-2026)
  13. 9.6.3 Europe Restless Legs Syndrome Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
  19. 9.6.9 Nordic Countries
10 China
  1. 10.1 China Restless Legs Syndrome Revenue (2021-2032)
  2. 10.2 China Restless Legs Syndrome Revenue by Type (2021-2032)
  3. 10.2.1 China Restless Legs Syndrome Revenue by Type (2021-2026)
  4. 10.2.2 China Restless Legs Syndrome Revenue by Type (2027-2032)
  5. 10.3 China Restless Legs Syndrome Revenue Share by Type (2021-2032)
  6. 10.4 China Restless Legs Syndrome Revenue by Application (2021-2032)
  7. 10.4.1 China Restless Legs Syndrome Revenue by Application (2021-2026)
  8. 10.4.2 China Restless Legs Syndrome Revenue by Application (2027-2032)
  9. 10.5 China Restless Legs Syndrome Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Restless Legs Syndrome Revenue (2021-2032)
  2. 11.2 Asia Restless Legs Syndrome Revenue by Type (2021-2032)
  3. 11.2.1 Asia Restless Legs Syndrome Revenue by Type (2021-2026)
  4. 11.2.2 Asia Restless Legs Syndrome Revenue by Type (2027-2032)
  5. 11.3 Asia Restless Legs Syndrome Revenue Share by Type (2021-2032)
  6. 11.4 Asia Restless Legs Syndrome Revenue by Application (2021-2032)
  7. 11.4.1 Asia Restless Legs Syndrome Revenue by Application (2021-2026)
  8. 11.4.2 Asia Restless Legs Syndrome Revenue by Application (2027-2032)
  9. 11.5 Asia Restless Legs Syndrome Revenue Share by Application (2021-2032)
  10. 11.6 Asia Restless Legs Syndrome Revenue by Country
  11. 11.6.1 Asia Restless Legs Syndrome Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Restless Legs Syndrome Revenue by Country (2021-2026)
  13. 11.6.3 Asia Restless Legs Syndrome Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Restless Legs Syndrome Revenue (2021-2032)
  2. 12.2 SAMEA Restless Legs Syndrome Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Restless Legs Syndrome Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Restless Legs Syndrome Revenue by Type (2027-2032)
  5. 12.3 SAMEA Restless Legs Syndrome Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Restless Legs Syndrome Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Restless Legs Syndrome Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Restless Legs Syndrome Revenue by Application (2027-2032)
  9. 12.5 SAMEA Restless Legs Syndrome Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Restless Legs Syndrome Revenue by Country
  11. 12.6.1 SAMEA Restless Legs Syndrome Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Restless Legs Syndrome Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Restless Legs Syndrome Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst